Mylan, GSK enter agreement over generic Paxil
PITTSBURGH, Pa. Mylan Inc. and its subsidiary Mylan Pharmaceuticals have entered into an agreement with GlaxoSmithKline in relation to Paroxetine Hydrochloride Extended-release tablets, the generic version of Paxil CR.
Under the agreement, Mylan is given the right to market all three strengths of the drug: 12.5 mg, 25 mg and 37.5 mg, beginning no later than Oct. 1, 2008. Mylan received eligibility for a 180-day marketing exclusivity for the 12.5 mg and 25 mg on June 29th.
The generic had U.S. sales of about $342 million for the 12 months ending June 30, 2007 for all three strengths.